Pharsight

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry	Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US5721244	ABBVIE	Combination of angiotensin-converting enzyme inhibitors with calcium antagonists as well as their use in drugs	Feb, 2015 (9 years ago)

Tarka is owned by Abbvie.

Tarka contains Trandolapril; Verapamil Hydrochloride.

Tarka has a total of 1 drug patent out of which 1 drug patent has expired.

Expired drug patents of Tarka are:

Tarka was authorised for market use on 22 October, 1996.

Tarka is available in tablet, extended release;oral dosage forms.

The generics of Tarka are possible to be released after 24 February, 2015.

Market Authorisation Date: 22 October, 1996

Treatment: NA

Dosage: TABLET, EXTENDED RELEASE;ORAL

Strength	Submission Date	ANDA(s) Filed	First applicant approval	Last patent expiry	180 day status
2 mg/180 mg and 2 mg/240 mg	09 Nov, 2007	1	26 May, 2010	24 Feb, 2015	Eligible
1 mg/240 mg	20 Feb, 2008	1	30 Aug, 2010	24 Feb, 2015	Eligible
4 mg/ 240 mg	24 Jul, 2007	1	05 May, 2010	24 Feb, 2015	Eligible

Strength	Dosage	Availability
2MG;180MG	TABLET, EXTENDED RELEASE;ORAL	Discontinued
4MG;240MG	TABLET, EXTENDED RELEASE;ORAL	Discontinued
2MG;240MG	TABLET, EXTENDED RELEASE;ORAL	Discontinued
1MG;240MG Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons	TABLET, EXTENDED RELEASE;ORAL	Discontinued

Tarka patents expiration